MDC Webinar: Rapid Research Rounds | Muscular Dystrophy Canada 2020 Neuromuscular Conference
Rapid Research Rounds
This session is an introduction to the 12 latest MDC funded research awardees. The projects span from early discovery, translational and clinical research as well as address critical gaps in Canada’s ecosystem. All of these projects were selected through competitive medical and scientific peer review process and have recently started. You will hear introductions to these projects, get to know the people behind the research and hear about the impact that donations raised by our neuromuscular community have on research.
For a full list of past MDC funded research please see: https://muscle.ca/access-help/research/projects-currently-funded/
NMD4C Members Involvement
We are excited to have strong representation from NMD4C members amongst those presenting, and encourage you to take this opportunity to learn about some of the work being done by our members!
For more information please visit the event page.
Register Now!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.